Mobile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study of Ad2/Hypoxia Inducible Factor (HIF)-1alfa/VP16 Administered by Intramuscular Injection to Patients with No ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-004068-21

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study of Ad2/Hypoxia Inducible Factor (HIF)-1alfa/VP16 Administered by Intramuscular Injection to Patients with No or Poor Option Chronic Critical Limb Ischemia

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety and tolerability of a single administration of Ad2/HIF-1alfa/VP16 by direct intramuscular (IM) injection in the treatment of patients with no or poor option chronic Critical Limb Ischemia (CLI)

Critère d'inclusion

  • Peripheral Arterial Disease (PAD) with no or poor Chronic Critical Limb Ischemia (CLI)

Liens